JB Chemicals Q4FY18 profit tanks 46 per cent

J. B. Chemicals & Pharmaceuticals reported its results for the quarter ended March 31, 2018.

The company’s standalone revenue for the quarter came in at Rs. 318.83 crore, registering 4.1 per cent yoy increase. The domestic formulations business continues to grow at better than industry growth rate. This growth is driven by increase in volumes and new introductions.

The slowdown in exports continued in the quarter. Margins in the US business was impacted due to competitive pricing in the market. Slow recovery of payments from many markets, resulted in a cautious approach to sales. Hence the overall performance of the division was subdued.

EBITDA for the quarter fell by 15.4 per cent yoy to Rs. 39.69 crore with a corresponding margin contraction of 288 bps. EBITDA margin for the quarter stood at 12.4 per cent.

The PAT for the quarter came in at Rs. 22.86 crore, yoy decline of 46 per cent.

Looking at the full year numbers, we see that revenue jumped by 5 per cent to reach Rs.1,254.73 crore while EBITDA fell by 9 per cent to Rs. 203.15 crore. The company reported net profit of Rs.128.08 crore, down 26 per cent yoy.

The company's board of directors have recommended a final dividend of Rs. 2 per equity share of the face value of Rs 2 each.

J. B. Chemicals & Pharmaceuticals is one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs.

On Friday, the stock opened at Rs. 299.85 per share and touched an intraday high and low of Rs. 301.30 and Rs. 292.85, respectively, on the BSE.